



November 21, 2023

The Manager- Listing **BSE Limited** Corporate Relationship Dept., 5th Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai - 400001

The Manager- Listing **National Stock Exchange of India Limited** Exchange plaza, 5th Floor, Plot No. C/1, G Block Bandra - Kurla Complex, Bandra (E), Mumbai - 400051

Dear Sir,

Sub: AstraZeneca Pharma India Limited receives permission to Import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for additional indication of Olaparib (Lynparza)

This is to inform that AstraZeneca Pharma India Limited has received permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for the additional indication of Olaparib film coated tablets of 100mg / 150mg (Lynparza).

Through this approval, Olaparib film coated tablets of 100mg/150mg (Lynparza) in combination with Abiraterone and Prednisone or Prednisolone is indicated for the treatment of adult patients with metastatic castration – resistant prostate cancer.

The receipt of this permission paves way for the launch of Olaparib film coated tablets of 100mg / 150mg (Lynparza) in India for the above specified additional indication, subject to the receipt of related statutory approvals, if any.

While the aforementioned permission was received end of business hours on November 17, 2023, some time was spent in good faith for evaluation of the contents and conditions laid by the regulator in the permission. We request you to take the above intimation on record.

Thanking you Yours faithfully

For AstraZeneca Pharma India Limited

Manasa. R **Company Secretary**

+91 80 6774 9628